Effect of icariin and simvastatin with different dosage ratios on rabbits’ radial fracture healing

doi:10.3969/j.issn.2095-4344.2013.15.007

Abstract

Abstract:

BACKGROUND: Icariin and simvastatin alone or in combination can promote the radial fracture healing of rabbits. But the best dosage ratio is still lack of basis.
OBJECTIVE: To investigate the effect of icariin and simvastatin with different dosage ratios on rabbits’ radial fracture healing.
METHODS: Forty-five healthy rabbits were enrolled to prepare bilateral radial fracture models, and then randomly divided into five groups: model group; bone morphogenetic protein-2 control group; and three experimental groups (ratio of icariin and simvastatin: 3:1, 1:1, 1:3). Model and bone morphogenetic protein-2 control groups were given normal saline by gastric perfusion. The three experimental groups were given icariin and simvastatin solution with dosage ratios of 3:1, 1:1, 1:3 by gastric perfusion. Model group and three experimental groups were injected normal saline at fracture site, while bone morphogenetic protein-2 control group was injected bone morphogenetic protein-2 solution. Gastric perfusion was performed for 6 consecutive weeks and local injection at fracture site lasted for 2 weeks.
RESULTS AND CONCLUSION: Bone morphogenetic protein-2 control group and 1:1 experimental group were the best followed by the 3:1 and 1:3 experimental groups, and the model group was the worst in the following aspects: growth and alteration of callus, recanalization of bone marrow cavity, bone mineral density and morphology of the fracture site. Icariin and simvastatin with different dosage ratios all can promote the radial fracture healing of rabbits. When the dosage ratio is 1:1, the combination of icariin and simvastatin can further promote fracture healing.

Key words: tissue construction, bone tissue construction, tissue construction and traditional Chinese medicine, radial fractures, icariin, simvastatin, bone morphogenetic protein-2, dosage ratio, , fracture healing, fracture healing model at the second stage

CLC Number:

R318

Wang Hui-ping, He Ai-yong, Chang Xiao-fei. Effect of icariin and simvastatin with different dosage ratios on rabbits’ radial fracture healing[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.15.007.

Figures/Tables 6

2.1 实验动物数量分析各组家兔均能良好耐受麻醉和手术，手术进行顺利。术后呈微跛步态，1周左右恢复正常步态。术后伤口无明显感染、化脓及坏死发生，2周左右完全愈合。术后饲养过程中，骨形态发生蛋白2组和淫羊藿苷∶辛伐他汀3∶1组分别于术后10 d和 12 d各死亡1只，立即予以补充，并顺延饲养时间。其余部分家兔出现腹泻症状，予以土霉素处理后，症状消失。 2.2 各组家兔大体观察结果骨折后第2周：模型组家兔前肢骨折线清晰，骨折断端无明显骨痂生长，骨折断端可以完全活动；骨形态发生蛋白2组家兔前肢骨折线比较模糊，骨折断端有较多骨痂生长，骨折断端可以轻微活动；淫羊藿苷∶辛伐他汀3∶1组家兔前肢骨折线可见，骨折断端有少量骨痂生长，骨折断端可以活动；淫羊藿苷∶辛伐他汀1∶1组家兔前肢骨折线比较模糊，骨折断端有大量骨痂生长，数量最多，形态最大，基本将骨折断端周围完全包绕，骨折断端基本不能活动；淫羊藿苷:辛伐他汀1∶3组家兔前肢和淫羊藿苷:辛伐他汀3∶1组情况相似，骨折线可见，骨折断端有少量骨痂生长，骨折断端可以活动。骨折后第4周：模型组家兔前肢骨折线仍可见，骨折断端有少量骨痂生长，骨皮质不连续；骨形态发生蛋白2组家兔前肢骨折线显著模糊，骨折断端有少量骨痂残留，骨皮质基本连续，表面欠光滑；淫羊藿苷∶辛伐他汀3∶1组家兔前肢骨折线比较模糊，骨折断端有较多骨痂生长，骨皮质欠连续，表面欠光滑；淫羊藿苷∶辛伐他汀1∶1组家兔前肢骨折线基本消失，骨折断端基本无骨痂残留，骨皮质基本连续，表面基本光滑；淫羊藿苷∶辛伐他汀1∶3组家兔前肢骨折线比较模糊，骨折断端有较多骨痂生长，骨皮质欠连续，表面欠光滑。骨折后第8周：模型组家兔前肢骨折线比较模糊，骨折断端有大量骨痂生长，骨皮质欠连续，表面欠光滑；骨形态发生蛋白2组家兔前肢骨折线消失，骨折断端无骨痂残留，骨皮质连续，表面光滑；淫羊藿苷∶辛伐他汀3∶1组家兔前肢骨折线显著模糊，骨折断端残留少量骨痂，骨皮质基本连续，表面欠光滑；淫羊藿苷∶辛伐他汀1∶1组家兔前肢骨折线消失，骨折断端无骨痂残留，骨皮质连续，表面光滑；淫羊藿苷∶辛伐他汀1∶3组家兔前肢骨折线显著模糊，骨折断端残留少量骨痂，骨皮质欠连续，表面欠光滑。综上所述，随着时间的推移，各组家兔前肢骨折处均逐渐愈合。在骨痂生长、改建和髓腔再通的时间方面，骨形态发生蛋白2、淫羊藿苷∶辛伐他汀1∶1组最早，淫羊藿苷∶辛伐他汀3∶1、淫羊藿苷∶辛伐他汀1∶3组居中，模型组最晚，且骨形态发生蛋白2与淫羊藿苷∶辛伐他汀组间差异无显著性意义。 2.3 各组家兔前肢骨折处X射线图像差异骨折后第2周：模型组家兔前肢骨折线清晰，骨折断端无骨痂影；骨形态发生蛋白2组家兔前肢骨折线比较模糊，骨折断端有较大的骨痂影；淫羊藿苷∶辛伐他汀3∶1组家兔前肢骨折线可见，骨折断端有较小的骨痂影；淫羊藿苷∶辛伐他汀1∶1组家兔前肢骨折线比较模糊，骨折断端有较大的骨痂影，而且数量和密度均较骨形态发生蛋白2组稍高；淫羊藿苷∶辛伐他汀1∶3组家兔前肢折处X射线图像和淫羊藿苷∶辛伐他汀3∶1组情况相似，骨折线可见，骨折断端有较小骨痂影，见图1。"

References

[1] Bao JR, Yang JW, Li SF, et al. Weisheng Yanjiu. 2005;34(2): 191-193.鲍加荣,杨继文,李树峰,等.淫羊藿苷对去卵巢大鼠骨质疏松症的影响[J].卫生研究,2005,34(2):191-193.

[2] Ji H, Liu K, Li SP, et al. Zhongguo Yaoke Daxue Xuebao. 2000;31(3):222- 225.季晖,刘康,李绍平,等.淫羊藿总黄酮对维A酸诱导大鼠骨质疏松症的防治作用[J].中国药科大学学报,2000,31(3):222- 225.

[3] Li QN, Liao JM, Wu T, et al. Zhongguo Yaoxue Zazhi. 1996; 31(8):467- 470.李青南,廖进民,吴铁,等. 淫羊藿提取液防治激素所致大鼠骨质疏松的实验研究[J].中国药学杂志,1996,31(8):467- 470.

[4] Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res. 2007;22(7):1072-1079.

[5] Zhang K. Zhongxiyi Jiehe Yanjiu. 2011;3(5):229-231.张昆.淫羊藿和胰岛素在糖尿病骨质疏松治疗中的配伍作用[J].中西医结合研究,2011,3(5):229- 231.

[6] Wang XW, He AY, Cai YZ, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(11):2030-2033.王欣文,何爱咏,蔡羽中,等.淫羊藿及骨形态发生蛋白2与家兔的骨折愈合[J].中国组织工程研究与临床康复,2011,15(11): 2030-2033.

[7] Yan ZS. Changsha: Central South University, 2011.闫振升.辛伐他汀及淫羊藿提取物促进兔桡骨骨折愈合实验研究[D].长沙:中南大学,2011.

[8] Ayukawa Y, Yasukawa E, Moriyama Y, et al. Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):336-342.

[9] Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999; 286(5446):1946-1949.

[10] Cai YZ, He AY, Wang XW, et al. Shengwu Yixue Gongcheng yu Linchuang. 2011;15(1):10-14.蔡羽中,何爱咏,王欣文,等.辛伐他汀与BMP-2促进兔桡骨骨折愈合的对比观察研究[J].生物医学工程与临床,2011,15(1):10-14.

[11] Liu DD, Wang F. Shiyong Yiyuan Linchuang Zazhi. 2006;3(3): 30-32.刘道德,王凡.淫羊藿对家兔骨折愈合过程中VEGF及TGF-β1表达的影响[J].实用医院临床杂志,2006,3(3):30-32.

[12] Wang CL, Li Y, Wang YX. Zhongguo Zhongyao Zazhi. 1998; 23(3):183-185.王昌林,李昱,王粤新.淫羊藿及其有效成分的药理研究概况[J].中国中药杂志,1998,23(3):183-185.

[13] Han GX, Wang ML, Zhang JD, et al. Yaoxue Shijian Zazhi. 2002;20(6):359-361.韩广轩,王麦莉,张军东,等.淫羊藿化学成分研究进展[J].药学实践杂志,2002,20(6):359-361.

[14] Wang MQ, Peng X, Gan QF. Xiandai Zhongyao Yanjiu yu Shijian. 2005;19(2):39-42.王明权,彭昕,甘棋锋.心叶淫羊藿的化学成分研究[J].现代中药研究与实践,2005,19(2):39-42.

[15] Li YB, Meng FH, Lu XM, et al. Zhongguo Zhongyao Zazhi. 2005;30(8):586-588.李遇伯,孟繁浩,鹿秀梅,等.淫羊藿化学成分的研究[J].中国中药杂志,2005,30(8):586-588.

[16] Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia, Part Ⅰ. 2005 ed. Beijing: Chemical Industry Press. 2005:219.国家药典委员会.中华人民共和国药典[M]. 2005年版.北京:化学工业出版社,2005:229.

[17] Qian WQ, Yin H, Sun HT. Zhongguo Yiyao Daobao. 2011; 8(36): 23-25.钱卫庆,尹宏,孙海涛.不同浓度淫羊藿苷对大鼠成骨细胞增殖、分化的影响[J].中国医药导报,2011,8(36):23-25.

[18] Li SL, Gao H, Zhang KH, et al. Beijing Daxue Xuebao: Yixue Ban. 2008;40(1):43-46.李盛林,高华,章魁华,等.淫羊藿对小鼠成骨细胞增殖、功能及凋亡的影响[J].北京大学学报(医学版),2008,40(1):43-46.

[19] Yin XX, Chen ZQ, Dang GT, et al. Zhongguo Zhongyao Zazhi. 2005;30(4):289-291.殷晓雪,陈仲强,党耕町,等.淫羊藿苷对人成骨细胞增殖与分化的影响[J].中国中药杂志,2005,30(4):289-291.

[20] Zhai YK, Li ZZ, Chen KM, et al. Zhongyaocai. 2011;34(6): 917-922.翟远坤,李志忠,陈克明,等.淫羊藿苷对体外培养乳鼠颅骨成骨细胞增殖、分化及成熟的影响[J].中药材,2011,34(6): 917-922.

[21] Zhang DW, Cheng Y, Zhang JC, et al. Zhongguo Yaoli Xue Tongbao. 2007;23(4):463-467.张大威,程岩,张金超,等.淫羊藿苷对破骨细胞的分化及骨吸收功能的影响[J].中国药理学通报,2007,23(4):463-467.

[22] Lv MB, Liu XY, Ge BF, et al. Zhongguo Gushang. 2007;20(8):529-531.吕明波,刘兴炎,葛宝丰,等.淫羊藿苷对破骨细胞活性的影响[J].中国骨伤,2007,20(8):529-531.

[23] Chen KM, Ge BF, Ma HP, et al. Zhongguo Guzhi Shusong Zazhi. 2008;14(9):642-645.陈克明,葛宝丰,马慧萍,等.淫羊藿苷对体外培养骨髓基质干细胞成骨性分化的影响[J].中国骨质疏松杂志,2008,14(9):642-645.

[24] Zhai YK, Wang MG, Li ZZ, et al. Zhonghua Zhongyiyao Zazhi. 2012;27(2):480-484.

翟远坤,王鸣刚,李志忠,等.淫羊藿苷含药血清对体外培养骨髓间充质干细胞增殖及成骨性分化的影响[J].中华中医药杂志,2012,27(2):480-484.

[25] Yang L, Zhang RH, Zhu XF, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010;14(19):3518-3522.杨丽,张荣华,朱晓峰,等.淫羊藿苷对大鼠间充质干细胞骨向分化过程中转化生长因子β1、骨形态发生蛋白2表达的影响[J].中国组织工程研究与临床康复,2010,14(19):3518-3522.

[26] Zhang AG, Cai JP, Tan XL, et al. Liaoning Zhongyi Zazhi. 2012; 39(1):158-161.张爱国,蔡建平,谭湘陵,等.五种中药对体外培养的大鼠骨髓间充质干细胞增殖活性的作用[J].辽宁中医杂志,2012,39(1): 158-161.

[27] Astrom AK, Jin D, Imamura T, et al. Current concepts growth factors in bone. Int Orthopedics.1998;22(6):410-416.

[28] Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355(9222): 2185-2188.

[29] Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283(24):3211-3216.

[30] Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000;355(9222):2218-2219.

[31] Maeda T, Matsunuma A, Kawane T, et al. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001; 280(3):874-877.

[32] Yang Y, Zhang LP, Li XG, et al. Jiepou Xuebao. 2007;38(5): 564-568.杨允,张立平,李晓光,等.辛伐他汀对成骨细胞血管内皮生长因子的表达和颅骨内血管新生的影响[J].解剖学报,2007,38(5): 564-568.

[33] Liu M, Zhu ZA, Tang TT. Zhongguo Guzhi Shusong Zazhi. 2008;14(2):101-105.刘铭,朱振安,汤亭亭.辛伐他汀对成骨样细胞MC3T3-E1增殖功能的影响[J].中国骨质疏松杂志,2008,14(2):101-105.

[34] Baek KH, Lee WY, Oh KW, et al. The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci. 2005;20(3):438-444.

[35] Corpataux JM, Naik J, Porter KE, et al. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res. 2005;129(1):52-56.

[36] Huang LY, Hu YY, Ma ZS, et al. Zhongguo Gushang. 2006; 19(7):420-423.黄鲁豫,胡蕴玉,马真胜,等.辛伐他汀抑制甲状旁腺素相关肽诱导的破骨细胞生成和功能[J].中国骨伤,2006,19(7):420-423.

[37] Yao C, Wang J, Wang DM, et al. Kouqiang Shengwu Yixue. 2011;2(3):161-164.姚淳,王珏,王东苗,等.他汀药物在骨改建中的作用研究进展[J].口腔生物医学,2011,2(3):161-164.

[38] Maritz FJ, Conradie MM, Hulley PA, et al. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol. 2001;21(10):1636-1641.

[39] Yao W, Farmer R, Cooper R, et al. Simvastatin did not prevent nor restore ovariectomy-induced bone loss in adult rats. J Musculoskelet Neuronal Interact. 2006;6(3):277-283.

[40] von Stechow D, Fish S, Yahalom D, et al. Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet Disord. 2003;4:8.

[41] Saraf SK, Singh A, Garbyal RS, et al. Effect of simvastatin on fracture healing--an experimental study. Indian J Exp Biol. 2007;45(5):444-449.

[42] Wang JW, Xu SW, Yang DS. Zhongguo Bingli Shengli Zazhi. 2009;25(2):377-382.王建卫,徐少文,杨迪生.辛伐他汀局部注射对大鼠骨质疏松性骨折愈合的影响[J].中国病理生理杂志,2009,25(2):377-382.

[43] Urist MR. Bone: formation by autoinduction. Science. 1965; 150(3698):893-899.

[44] Croteau S, Rauch F, Silvestri A, et al. Bone morphogenetic proteins in orthopedics: from basic science to clinical practice. Orthopedics. 1999;22(7):686-697.

[45] Zhang YG, Lu SB, Wang JF, et al. Zhonghua Waike Zazhi. 1999;37(7):399-402.张永刚,卢世璧,王继芳,等.BMP-2、TGF-β、bFGF 在引导性骨再生中的表达[J].中华外科杂志,1999,37(7):399-402.

[46] Kübler N, Urist MR. Cell differentiation in response to partially purified osteosarcoma-derived bone morphogenetic protein in vivo and in vitro. Clin Orthop Relat Res. 1993;(292):321-328.

[47] Valentin-Opran A, Wozney J, Csimma C, et al. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res. 2002;(395):110-120.

[48] Zhang M, Lu HS, Du JY. Shiyong Guke Zazhi. 2004;10(3): 219-221.张民,卢汉生,杜靖远.骨形态发生蛋白复合同种松质骨载体修复节段性骨缺损的实验研究[J].实用骨科杂志,2004,10(3): 219-221.